Why Did Bioxcel Therapeutics Drop 6.69%?

On August 5, 2025, Bioxcel Therapeutics experienced a 6.69% drop in pre-market trading, reflecting a significant decline in investor sentiment.

Analysts have been closely monitoring Bioxcel Therapeutics, with a mix of ratings ranging from Buy to Sell. H.C. Wainwright reiterated a Buy rating, citing the company's upcoming SERENITY At-Home trial results and pre-sNDA submission. The firm's price target for Bioxcel Therapeutics is $8 per share, based on a discounted cash flow assessment.

Mizuho Securities, on the other hand, lowered its price target to $2, reflecting updated financials and recent financings. The firm maintained a Hold rating, indicating a more cautious outlook. Bank of America Securities also reiterated a Sell rating, suggesting that the company faces significant challenges.

Despite the varied analyst opinions, Bioxcel Therapeutics has shown resilience in meeting earnings and sales estimates. The company has outperformed its industry in the past year, beating EPS estimates 100% of the time and sales estimates 50% of the time. This performance has contributed to a consensus rating of Hold, with 2 Buy ratings, 1 Hold rating, and 1 Sell rating.